AUS
NZ
UK
CA
USA
IND
Healthcare
ASX 200 Tech Star Under Pressure: Is Pro Medicus Losing Its Shine?
April 09, 2026 10:30 AM AEST| By SamPro Medicus faces valuation scrutiny despite strong growth, reflecting shifting sentiment within the ASX 200 healthcare technology sector.
ASX All Ordinaries Healthcare Stock: Cogstate Surge Sparks Fresh Debate
April 09, 2026 10:10 AM AEST| By SamCogstate shares surge on strong contract growth and healthcare demand, highlighting its role in the All Ordinaries healthcare technology sector.
AI Healthcare Buzz: Artrya Shares Surge on Imaging Momentum
April 09, 2026 10:02 AM AEST| By SamArtrya gains attention as AI-driven healthcare imaging demand rises, highlighting growth opportunities within the All Ordinaries and evolving medical technology sector.
Mesoblast (ASX:MSB) ASX 200 Biotech Sector Activity Explained?
April 09, 2026 03:12 AM AEST| By SamMesoblast reflects ASX 200 and ASX 300 biotechnology sector activity, highlighting clinical development processes and healthcare innovation participation.
All Ordinaries: Paradigm Biopharma Files to List 6M Shares
April 08, 2026 08:09 PM AEST| By SamParadigm Biopharmaceuticals (ASX:PAR) applies for new shares on all ordinaries, adjusting the capital structure through options conversions while remaining compliant with ASX listing rules.
ASX Update: Artrya All Ordinaries Share Activity
April 08, 2026 05:53 PM AEST| By SamArtrya reflects ASX 300 and All Ordinaries healthcare technology sector activity through share quotation, highlighting capital structure processes and medical innovation.
ASX 200 Update: Telix Pharmaceuticals Sector Focus
April 08, 2026 02:44 PM AEST| By SamTelix Pharmaceuticals operates within the ASX 200 biotechnology sector, focusing on radiopharmaceutical development and contributing to healthcare market participation.
Mesoblast Seeks ASX 200 Quotation for New Shares
April 08, 2026 12:36 PM AEST| By SamMesoblast advances share quotation within the ASX 200 framework, reflecting capital structure adjustments and ongoing participation in the biotechnology sector.
Telix ASX 200 Healthcare Revenue Activity Update
April 07, 2026 02:28 PM AEST| By SamTelix operates within the healthcare sector, with radiopharmaceutical development and revenue activity reflecting ongoing innovation across ASX 200 and ASX 300 market segments.
ASX 20: What US tariffs mean for CSL and Mayne Pharma shares
April 07, 2026 02:23 PM AEST| By SamCSL and Mayne Pharma assess impact of US pharmaceutical tariffs, with both expecting limited operational disruption.
Beamtree (ASX:BMT) All Ordinaries AI Healthcare Sector Focus
April 07, 2026 01:50 PM AEST| By SamBeamtree operates in the healthcare technology sector, where AI-driven platforms and data systems support evolving medical services within the All Ordinaries market landscape.
Ramsay’s Big Shift: What’s Changing at RHC Now?
April 07, 2026 10:53 AM AEST| By SamRamsay Health Care’s strategic shift toward Australian operations highlights a renewed focus on efficiency, cost management and operational clarity, reshaping how the company is positioned within the evolving healthcare landscape.
ASX All Ordinaries Biotech Stock Update on Starpharma
April 07, 2026 09:48 AM AEST| By SamStarpharma’s share issuance highlights capital management within the biotechnology sector, reflecting research-driven operations and participation across All Ordinaries.
Can Lumos (ASX:LDX) Redefine Rapid Infection Testing?
April 02, 2026 10:20 PM AEDT| By SamLumos (ASX:LDX) advances US expansion with FebriDx, enhancing rapid infection diagnosis and supporting efficient clinical decisions across healthcare settings.
Is Vitura Health Entering a New Growth Phase?
April 02, 2026 08:27 PM AEDT| By SamVitura Health’s leadership change highlights its evolving digital healthcare strategy, focusing on specialised treatments, patient access, and operational transformation within the Australian healthcare sector.
Is CSL’s Buy-Back Strategy Redefining Its Market Narrative?
April 02, 2026 06:56 PM AEDT| By SamCSL’s ongoing buy-back strategy highlights capital discipline while balancing growth investments, margin recovery, and structural changes shaping its evolving market narrative.
Imagion Biosystems Clarifies Filing, Reviews Compliance on All Ords
April 02, 2026 05:23 PM AEDT| By SamImagion Biosystems addresses filing delay aligned with the all ordinaries, covering compliance updates, convertible note repayment, and ongoing progress in MagSense imaging technology development.
Is 4DMedical Expanding Capital Base Amid All Ords Index Move?
April 02, 2026 04:36 PM AEDT| By Sam4DMedical progresses share quotation aligned with the all ordinaries, reflecting capital expansion and ongoing development of advanced respiratory imaging solutions in healthcare technology.
Lumos Diagnostics Jumps on US Clearance Amid Iran-US War?
April 02, 2026 04:22 PM AEDT| By SamLumos Diagnostics progresses FebriDx deployment aligned with the all ordinaries, covering regulatory milestones, distribution strategy, reimbursement pathways, and manufacturing expansion in healthcare diagnostics.
All Ordinaries Healthcare Stock Share Issue Draws Focus
April 02, 2026 03:37 PM AEDT| By SamAll Ordinaries healthcare activity highlights Racura Oncology share quotation process, reflecting capital structure developments and biotechnology sector participation across the market.
Advertise your brand on Kalkine Media